INDP: Indaptus Therapeutics Growth-Adjusted Market Cap to Net Income

Indaptus Therapeutics (INDP) maintains significant pricing power through its innovative method of immune activation via bacterial technologies. The PEG growth stock screener clearly illustrates the dynamics of this potential, where the parameter value equals 0.00. However, the early stage of development and a lack of liquidity create certain risks. The business foundation currently relies on primary clinical tests and narrow research alliances.

Indaptus Therapeutics (INDP) is developing a proprietary tumor immunotherapy technology, the future profitability of which depends directly on clinical trial results. The PEG ratio measures the cost of a unit of profit relative to its growth rate, allowing the calculated PEG level to determine if an asset is undervalued when the value is below one and to avoid purchasing an overheated business at its valuation peak.